SF-6D (n=21) 10 (6%) 6 (6%) 11 (11%)
Abbreviations: ACS = Acute coronary syndrome; UK = United Kingdom; USA = United States of America *The numbers do not add to the totals, as 63 studies report on two or more types of CV conditions, 33 studies reported utilities using more than one method of elicitation, and 12 studies compared utilities for different types of respondents. †Top 10 countries reported across the review reported here. 
Identification

Screening
Grey literature searches and bibliography check (n=7)
Papers included (n=290)
Excluded (n=861):
Study does not report a utility value:
No utility data for CV event of interest:
Study only reports secondary utility data (i.e., cost-utility models or literature reviews): (n=127) 
INTRODUCTION
Health state utilities are values on a scale anchored to 0 (dead) and 1 (full health) representing the strength of preferences for health states. Utility scores can be used to populate quality-adjusted life years (QALY) in health economic modeling to evaluate and compare the value of new and existing treatment options.
Several different methods for utility elicitation are available. Standard questionnaire-based methods such as the EuroQOL five dimensions (EQ-5D) index, the Short Form six dimensions (SF-6D), and health utility indices (HUI) are typically used to measure patients' own utility scores. Approaches such as the standard gamble (SG) or time trade-off (TTO) can also be used for patients, as well as for eliciting hypothetical vignette-based utilities from general population respondents. The optimal selection of the method for utility elicitation depends largely on the purpose of the study and the attributes/condition that the utility score is meant to represent.
With a variety of measures, types of respondents, settings, and populations evaluated, utility scores can vary substantially. A systematic review was conducted to evaluate the differences and drivers among reported health state utilities for stroke, heart failure, and acute coronary syndrome (ACS, including MI and angina evaluated independently).
An SLR was initiated to identify studies generating utility data for the following CV events: stroke, heart failure, and ACS. The criteria for selecting studies are outlined in Table 1. MEDLINE and Embase were searched from 1992 through January 23, 2015. An update to capture the most recent literature and utilities for heart failure was conducted on August 3, 2015. Grey literature searches and manual bibliography reviews were also conducted.
Across databases, 4,341 citations were screened and 290 articles ultimately met the inclusion criteria for the review, (Figure 1 , Table 2 ) reporting utility values for at least one of the CV events of interest.
One hundred and fifty-five articles reported a health state utility for stroke, 100 studies reported a utility for heart failure, and 98 studies reported a utility for ACS; 63 of these studies reported utilities for more than one CV event.
Reported utilities for CV events ranged widely (stroke: -1.99-0.99; heart failure: 0.199-0.995; ACS: 0.11-1). This variation appeared to stem from several factors, including differences in the patient populations evaluated, disease severity, methodology, and timing of the assessment relative to the occurrence of the onset of the CV condition.
More severe disease was associated with lower utility values for stroke (mild: 0.55-0.961; severe: -1.57-0.7), heart failure (mild: 0.56-0.99; severe: 0.235-0.675), and angina (mild: 0.76-0.983; severe: 0.54-0.944) (Figure 2 ).
Within studies, utilities were sensitive to time since event for MI, but not stroke or heart failure.
-Stroke: Of the 24 studies reporting average EQ-5D scores over time, 12 showed improvement, six showed fluctuations, six showed no or minimal improvement, and three showed declines. The studies that showed improvements over time were more likely to be smaller cohort studies or trials, conducted exclusively in ischemic stroke, and evaluating patients with severe stroke.
-Heart failure: Across studies, utility values for chronic heart failure remained broadly stable over time, though there were exceptions in some individual studies. Two-thirds of average utility scores changed less than 0.05 after six or more months following study enrollment. Patients with severe heart failure were more likely to see decreases in average utility scores.
-ACS: The data suggest that utility values for patients with angina improve initially over time since enrollment with effective treatment, regardless of whether the patients have stable or unstable disease. For example, one study of MI patients also found that EQ-5D utility values recovered over three months following hospital discharge. However, none of the studies examined TTO or EQ-5D utility values immediately after an MI, but rather one month to 24 months after an event.
Since utility values would likely be higher weeks or months after an event than immediately after it, it is not clear how much utility values may increase over time after an MI.
Approaches to utility elicitation impacted values: in all CV conditions assessed, the EQ-5D yielded low utility estimates more often than other methods; the SF-6D resulted in very narrow ranges of estimates (0.55-0.88) (Figure 3 ).
-Stroke: The EQ-5D more often yielded lower utility scores compared to the other methods, whereas the SF-6D and other methods yielded extreme values less often.
-Heart failure: The greatest range of values was reported for EQ-5D and TTO utilities, while the most narrow and least extreme range of utility values was reported for SF-6D utilities.
-ACS: All of the utility methods yielded similar results for angina, although there were some very low values for EQ-5D and TTO.
Across studies, utility values for stroke and heart failure derived from general population respondents were similar to those derived from patients who experienced the conditions themselves; however, ACS patients generally reported lower values than general population respondents. Four head-to-head comparisons, all evaluating stroke, found that general population respondents yielded slightly lower or similar values to patients who had experienced a stroke.
Changes observed by geographic region may have been due to methodological differences. In the UK, EQ-5D values for stroke (lowest quarter: -0.14-0.46) were more often lower than those in the US (0.1-0.66), or those in the UK elicited by other methods (0.19-0.55), potentially due to differences in the tariff algorithms used to calculate the EQ-5D index score (Figures 4 & 5) .
Differences in population contribute to variation across studies, which is particularly evident when observing differences by disease severity. The timing of elicitation since the event also impacts utility scores for ACS, and possibly for stroke.
The method of utility elicitation also impacted utility values. The EQ-5D, for example, reported low utility values more often than other measures. The SF-6D often resulted in narrow ranges of estimates. Furthermore, the tariff used to calculate indirect utilities also impacted scores, particularly for the EQ-5D scores calculated with the US tariff, which showed higher values.
Utility values for CV events vary widely and should be selected with attention to disease severity, time since event (for ACS in particular), country, and elicitation method.
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